{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-027336","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2025-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.602904+00:00","generated_at":"2026-05-26T03:58:47.055297+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.72,"calibrated_materiality_score":0.72,"confidence":"high","headline":"NewAmsterdam reports FY2024 net loss $241.6M, cash $834M; EMA submission on track for 2H25","bullets":["Cash, cash equivalents and marketable securities totaled $834.2M at Dec 31, 2024, up from $340.5M.","Revenue of $45.6M (FY2023: $14.1M) driven by a clinical milestone and cost reimbursement.","Net loss widened to $241.6M from $176.9M; R&D spend fell to $151.4M while SG&A rose to $70.4M.","Phase 3 BROADWAY met primary endpoint with 33% LDL-C reduction; TANDEM FDC achieved 49% reduction; BROOKLYN showed 36% reduction.","EMA submission planned for 2H25 via partner Menarini; USPTO issued obicetrapib solid-form patent until July 2043."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-027336","json":"https://secwatch.observer/filing/0000950170-25-027336.json","markdown":"https://secwatch.observer/filing/0000950170-25-027336.md","text":"https://secwatch.observer/filing/0000950170-25-027336.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025027336/0000950170-25-027336-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025027336/nams-20250226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T03:58:47.055297+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}